Zeng DX, et al. - In this retrospective analysis of 13 advanced lung squamous cell carcinoma patients, the efficacy and safety of apatinib (a small molecule inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase) were tested. These patients received apatinib monotherapy (250–425 mg/day) for second-line or fourth-line therapy after disease progression with doublet chemotherapy or docetaxel as the first-line treatment. Apatinib monotherapy offered median PFS of 3.1 months, 46.2% total disease control rate, 15.4% (2/13) objective remission rate, with vomiting and hypertension as main advert effects. After apatinib monotherapy, partial response and stable disease were achieved by 2 patients and 4 patients, respectively, and seven patients achieved progression disease. Overall, apatinib might serve as rescue therapy in advanced lung squamous cell carcinoma.